What study would prove whether HBOT works after a hair transplant?
The study that would settle the HBOT questionWhat a decisive study would look like, and how far the four published papers fall short.
This study has not been done. Nothing in this diagram is data. Patients from several centers several centers just to get enough patients, which demands its own consistency Randomize HBOT arm Daily sessions after surgery, as in the published protocols. Sham pressure control Same chamber, mild pressure and room air instead of the oxygen dose: same schedule, same room, same pressure in the ears. Standardized surgery one fixed protocol and only a few surgeons Time out of body Handling and storage solution Incision size and depth Density in the test field Surgeon skill Patient medications, reported Blinded hair count at twelve months Hairs counted in a tattooed 1 cm² field in the recipient area by someone blinded to the group. At twelve months, not nine. Also: early shedding and inflammatory complications. The binding constraint After well performed FUE, most grafts already survive: 93.8% of controls in the Fan trial, so any gain would be a small lift on a high number. Fan trial: 17 per group Needed: several hundred per group About a hundred times too few. Still open: the dose The two published protocols differ. 2.0 ATA, 60 minutes, for 7 days 2.4 ATA, 90 minutes, for 6 days Nobody knows which is better, or if fewer sessions would work just as well. Here it is used off label, and nobody has worked out the right dose. Nobody has a reason to fund the study: HBOT cannot be patented, and clinics already sell it without one.
Hyperbaric oxygen

What study would prove whether HBOT works after a hair transplant?

It would take a randomised trial across several centres with several hundred patients, twelve months of follow-up, blinded hair counts in a marked area and a control group given sham pressure.

Summary

Settling the question would take a randomised trial across several centres with several hundred patients. It would have to follow them for twelve months, count hairs blind in a marked patch of the recipient area and include a control group given sham pressure. The four published papers are a long way from that kind of design.

Why do we still not know whether HBOT improves hair transplant results?

Because the little that has been published was never designed to answer the question. All we have is one randomised trial, one case report, one pilot study in healthy people and one letter to the editor. The problem is not that the papers were poor. Once you look at what a study capable of settling the matter would actually require, it becomes clear what is missing today.

Four publications are all we have: one randomised trial, one case report, one pilot study in volunteers and one letter to the editor. After them, we still don't know whether hyperbaric oxygen leads to a better hair transplant result. That isn't down to sloppiness. None of them was designed to answer exactly that question.

That's why it pays to sketch out what it would take. You can then see what current knowledge is missing, and you get a yardstick to hold any new study up against when a clinic shows it to you.

How many patients would a study need to find a real HBOT effect?

Several hundred per group. When FUE is done well, most grafts already survive, 93.8 % in the control group of the Fan study. Any gain from an add-on will therefore be a small improvement to a figure that is already high. To detect a gain of two or three points around 95 %, each group needs several hundred participants. The Fan study had seventeen.

The number of participants is the constraint everything else hangs on. After a competent FUE, the vast majority of grafts already survive. In Fan's control group the figure was 93.8 %. What an add-on could realistically contribute, then, is a small absolute improvement to a number that is already high.

If you want to detect a gain of two or three percentage points when both rates lie somewhere between 90 and 100 %, each group needs several hundred patients. Fan and colleagues had seventeen per group, far below a tenth of what is needed. That explains why the null finding for survival tells us so little.

A study that could give the answer would have to run across several centres just to recruit enough patients. That brings its own demand that everyone does things the same way.

Which outcomes should a decisive study measure?

It would need to count hairs in a defined, tattooed area of one square centimetre in the recipient area, rather than report a single overall survival percentage. The count would have to be done by someone who doesn't know who got what. It would have to take place at the one-year check and not after nine months, because density is still developing. Early shedding and inflammation would need to be tracked as additional outcomes, so the findings we have can be confirmed.

  • Counts in a tattooed area rather than a single overall survival percentage. Hair research marks out one square centimetre, photographs the area and counts the hairs there before the procedure and at follow-up. That is how you get a figure that stands up to scrutiny.
  • Done by someone who doesn't know which group the patient is in. Ideally the count should be made on photos where nothing reveals who received the treatment.
  • At the one-year check, not after nine months. Final density is usually assessed around the first anniversary. Measure at nine months and you are measuring something that isn't finished.
  • Early shedding and inflammatory symptoms as secondary outcomes. That is where the existing study found an effect, and that finding needs to be confirmed.

Why does the study need a control group given sham pressure?

In the study that exists, everyone knew who was getting HBOT. The treatment group came to the centre every day and received a lot of follow-up, while the control group went home. That alone could explain some of the difference in wellbeing and shedding. If the control group breathes ordinary air under light pressure, both groups have the same daily routine, and only then can the effect of the oxygen itself be isolated.

Of everything missing from the study design, this is the most obvious gap. It is also the one that would add the most credibility.

When no one is blinded, the HBOT group comes to the centre seven days in a row. They are seen daily and get plenty of attention and reassurance during the period when patients are at their most anxious. The control group is sent home. It's reasonable to think that some of the difference in itching and wellbeing, perhaps also in measured shedding, comes from different amounts of contact with the clinicians and not from the oxygen.

Sham treatment is a known method in hyperbaric research. Participants in the control group sit in the chamber like everyone else but breathe ordinary air at a low pressure, not oxygen at a treatment dose. Everyone then has the same schedule, the same experience of being shut in and the same pressure in the ears. It takes effort, but the method is established. Without it, the attention effect can't be separated from the treatment effect.

Which surgical factors would need to be kept the same in a decisive study?

Everything that affects survival would need to be controlled: the time grafts spend outside the body, how they are handled, the solution they are kept in, the size and depth of the recipient sites, the density and the surgeon's skill. Parsley and Perez-Meza list these factors in their review. That requires everyone to operate the same way, and ideally only a few surgeons taking part. The background medicines patients use would also need to be described, which the Fan study did not do.

Many surgical factors decide whether a graft survives. They include how long it spends outside the body, how it is handled and what it is stored in. They also include how large and deep the recipient sites are, how densely the grafts are placed and how skilled the surgeon is. Parsley and Perez-Meza have brought these factors together in a review of what determines whether follicular grafts grow.

If they aren't controlled, the noise becomes bigger than the effect you are trying to find. The study would therefore need one surgical protocol for everyone, ideally a small number of surgeons, fixed routines for handling the grafts and a set density in the study area.

Patients' medicines would also need to be described. Dong and Jin criticised the Fan study for being unclear about how hair loss medicines were handled when patients were excluded. Any new study should be built to avoid that criticism.

Which questions about dosing remain unanswered?

Even a successful study would not settle the dosing. The protocols in the literature differ: seven days of 60 minutes at 2.0 ATA, or six days of 90 minutes at 2.4 ATA. Nobody knows which works best, or whether fewer sessions would be just as good. For this off-label use, no studies have ever been done to find the right dose.

Even with a positive finding, the practical questions would remain, because the two regimens in the literature differ. One gives 60 minutes at 2.0 ATA every day for seven days. The other gives 90 minutes at 2.4 ATA every day for six days. Which is better is unknown. Nobody knows either whether fewer sessions would achieve the same.

Heyboer and colleagues make the same point about hyperbaric medicine in general. They call for better knowledge of the benefits and risks of different pressure levels and treatment times, so protocols can be made consistent from one institution to the next. For cosmetic off-label use, not a single trial has tried to find the right dose.

Why is such a study unlikely to happen any time soon?

Because nobody stands to profit from paying for it. Nobody can patent oxygen under pressure, so there is no drug company that will sponsor the trial. There is little public research money for add-ons to cosmetic procedures. And clinics already sell the treatment without such a study. The most likely outcome is that HBOT will go on being sold as a premium add-on for many years, on a basis of four studies.

Several hundred patients, several centres, twelve months of follow-up and a sham control cost a lot of money. No drug company will pay, because there is no product to license. Public research funding for add-ons to cosmetic procedures is scarce. And the clinics that would host the trial already make money on the treatment without it.

It's not an encouraging assessment, but it is an honest one. Most likely, HBOT will be sold as a premium add-on for a long time to come, on the same thin basis of four studies.

So the advice to you stands. Hold the offer up against the only thing that is documented. Fewer people shed hair in the first weeks, and fewer are bothered by itching and folliculitis. No measurable gain in the final result has been found.

Sources

  1. Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
  2. Dong X, Jin X. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia [letter to the editor]. Journal of Cosmetic Dermatology, 2021. doi.org/10.1111/jocd.14131
  3. Parsley WM, Perez-Meza D. Review of factors affecting the growth and survival of follicular graft. Journal of Cutaneous and Aesthetic Surgery, 2010;3(2). jcasonline.com
  4. Heyboer M, Sharma D, Santiago W, McCulloch N. Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified. Advances in Wound Care, 2017;6(6):210-224. pubmed.ncbi.nlm.nih.gov/28616361
  5. Lee HY, Lee JY, Kim SC, Lee Y. Preliminary Effects of Hyperbaric Oxygen Therapy on Hair Follicle Characteristics in Healthy Subjects. Bioengineering, 2026;13(2):240. doi.org/10.3390/bioengineering13020240
  6. Giardiello F, De Medeiros Quirino L, Brigante R, Chumak M. Hyperbaric Oxygen Therapy for Enhanced Postoperative Recovery in Hair Transplantation. Cureus, 2025;17(12):e99635. doi.org/10.7759/cureus.99635

This article summarises published research and standard clinical practice. It is meant as general information and is not medical advice. Nor does it replace the advice you get from your own surgical team. If your team tells you something different from what is written here, follow your team.

Free assessment

Wondering what's possible for your hair?

Send three sharp photos of your hair, from the front, the top and the back. You'll get an honest answer on what can be done, roughly how many grafts it would take and what it costs.

  • Free and with no obligation
  • Photos are assessed by the clinic's medical team
  • Replies usually within an hour in the daytime
See more before and after photos

3 photos: from the front, from above and from the back (crown). The photos are what make the analysis accurate. If you don't have them to hand, you can send them on WhatsApp later.

Your details are kept confidential, and the clinic will reply to you on WhatsApp or by email.

What does this mean for you?

A study tells you something about groups. Only a doctor who has seen your photos can say what applies to your hair. The medical team at the clinic at the top of our ranking offers a free assessment.

Goes to the clinic at the top of our ranking.

Ask the clinic on WhatsAppA reply from the clinic, usually within an hour during the day.
Ask the clinic